Sharma Chandan, Hemler Martin E
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Antioxidants (Basel). 2022 May 12;11(5):960. doi: 10.3390/antiox11050960.
Silencing of DHHC3, an acyltransferase enzyme in the DHHC family, extensively upregulates oxidative stress (OS). Substrates for DHHC3-mediated palmitoylation include several antioxidant proteins and many other redox regulatory proteins. This helps to explain why DHHC3 ablation upregulates OS. DHHC3 also plays a key role in cancer. DHHC3 ablation leads to diminished xenograft growth of multiple cancer cell types, along with diminished metastasis. Furthermore, DHHC3 protein is upregulated on malignant/metastatic cancer samples, and upregulated gene expression correlates with diminished patient survival in several human cancers. Decreased primary tumor growth due to DHHC3 ablation may be partly explained by an elevated OS → senescence → innate immune cell recruitment mechanism. Elevated OS due to DHHC3 ablation may also contribute to adaptive anticancer immunity and impair tumor metastasis. In addition, DHHC3 ablation disrupts antioxidant protection mechanisms, thus enhancing the efficacy of OS-inducing anticancer drugs. A major focus has thus far been on OS regulation by DHHC3. However, remaining to be studied are multiple DHHC3 substrates that may affect tumor behavior independent of OS. Nonetheless, the currently established properties of DHHC3 make it an attractive candidate for therapeutic targeting in situations in which antioxidant protections need to be downmodulated, and also in cancer.
DHHC家族中的酰基转移酶DHHC3的沉默会广泛上调氧化应激(OS)。DHHC3介导的棕榈酰化作用的底物包括几种抗氧化蛋白和许多其他氧化还原调节蛋白。这有助于解释为什么敲除DHHC3会上调氧化应激。DHHC3在癌症中也起着关键作用。敲除DHHC3会导致多种癌细胞类型的异种移植生长减少,同时转移也减少。此外,DHHC3蛋白在恶性/转移性癌症样本中上调,基因表达上调与几种人类癌症患者生存率降低相关。敲除DHHC3导致原发性肿瘤生长减少,部分原因可能是氧化应激升高→衰老→先天性免疫细胞募集机制。敲除DHHC3导致的氧化应激升高也可能有助于适应性抗癌免疫并损害肿瘤转移。此外,敲除DHHC3会破坏抗氧化保护机制,从而提高诱导氧化应激的抗癌药物的疗效。迄今为止,主要关注点一直是DHHC3对氧化应激的调节。然而,可能独立于氧化应激影响肿瘤行为的多种DHHC3底物仍有待研究。尽管如此,DHHC3目前已确定的特性使其成为在需要下调抗氧化保护的情况下以及在癌症治疗中进行靶向治疗的有吸引力的候选对象。